Assessment of Novel iloperidone- and idebenone-loaded Nanostructured Lipid Carriers: Brain Targeting Efficiency and Neuroprotective Potential

Abstract

BACKGROUND: To evaluate the outcome of combining iloperidone with idebenone in the form of brain-targeted nanostructured lipid carrier (NLC) on the expression of endogenous antioxidant enzymes present in the brain, and hence establish the neuroprotective activity. RESULTS: The combination NLC demonstrated good targeting potential (>85%) as compared with pure iloperidone (22.21%). The levels of various endogenous antioxidant enzymes present in the brain were reduced significantly (p < 0.001) in case of 28 days repeated administration of pure iloperidone, while administration of the combination NLC helped to restore the levels of these enzymes. CONCLUSION: Combining iloperidone with idebenone and converting into NLC has contributed in effectively reducing oxidative stress in the brain and helped in reversing the catalepsy induced by repeated iloperidone administration.